Syntara Future Growth

Future criteria checks 0/6

Syntara's revenue is forecast to decline at 59.4% per annum while its annual earnings are expected to grow at 17.7% per year. EPS is expected to grow by 42.8% per annum.

Key information

17.7%

Earnings growth rate

42.8%

EPS growth rate

Pharmaceuticals earnings growth	28.3%
Revenue growth rate	-59.4%
Future return on equity	n/a
Analyst coverage	Low
Last updated	05 Mar 2024

Recent future growth updates

Recent updates

Syntara Limited's (ASX:SNT) Low P/S No Reason For Excitement

Mar 14

We're Hopeful That Pharmaxis (ASX:PXS) Will Use Its Cash Wisely

Feb 28

Shareholders May Not Be So Generous With Pharmaxis Ltd's (ASX:PXS) CEO Compensation And Here's Why

Oct 27

Key Things To Understand About Pharmaxis' (ASX:PXS) CEO Pay Cheque

Mar 01

We Think Pharmaxis (ASX:PXS) Can Afford To Drive Business Growth

Jan 04

Earnings and Revenue Growth Forecasts

ASX:SNT - Analysts future estimates and past financials data (AUD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
6/30/2026	5	-4	-4	-4	1
6/30/2025	4	-13	-10	-10	1
6/30/2024	12	-8	-6	-6	1
12/31/2023	19	-11	-11	-11	N/A
9/30/2023	12	-18	-16	-16	N/A
6/30/2023	19	-11	-7	-7	N/A
3/31/2023	18	2	-7	-7	N/A
12/31/2022	8	-2	-12	-12	N/A
9/30/2022	18	2	-11	-11	N/A
6/30/2022	16	-2	-17	-16	N/A
3/31/2022	14	-16	-12	-12	N/A
12/31/2021	19	-12	-8	-8	N/A
9/30/2021	28	-1	5	5	N/A
6/30/2021	24	-3	2	3	N/A
3/31/2021	27	5	-2	-1	N/A
12/31/2020	22	-4	-5	-5	N/A
9/30/2020	12	-13	-11	-11	N/A
6/30/2020	13	-14	-14	-13	N/A
3/31/2020	13	-21	-13	-12	N/A
12/31/2019	13	-18	-14	-13	N/A
9/30/2019	13	-18	N/A	N/A	N/A
6/30/2019	12	-20	-21	-20	N/A
3/31/2019	7	-27	-20	-19	N/A
12/31/2018	22	-12	-4	-3	N/A
9/30/2018	21	-22	-13	-12	N/A
6/30/2018	49	6	11	12	N/A
3/31/2018	51	10	N/A	N/A	N/A
12/31/2017	37	-1	-2	-2	N/A
9/30/2017	36	7	N/A	9	N/A
6/30/2017	9	-18	N/A	-15	N/A
3/31/2017	8	-16	N/A	-13	N/A
12/31/2016	7	-16	N/A	-14	N/A
9/30/2016	8	-14	N/A	-15	N/A
6/30/2016	10	-16	N/A	-12	N/A
3/31/2016	47	16	N/A	21	N/A
12/31/2015	48	14	N/A	29	N/A
9/30/2015	49	21	N/A	27	N/A
6/30/2015	47	18	N/A	22	N/A
3/31/2015	5	-34	N/A	N/A	N/A
12/31/2014	8	-38	N/A	-29	N/A
9/30/2014	5	-51	N/A	N/A	N/A
6/30/2014	9	-52	N/A	-28	N/A
3/31/2014	5	-44	N/A	N/A	N/A
12/31/2013	6	-43	N/A	-32	N/A
9/30/2013	4	-43	N/A	N/A	N/A
6/30/2013	3	-44	N/A	-35	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: SNT is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: SNT is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: SNT is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: SNT's revenue is expected to decline over the next 3 years (-59.4% per year).

High Growth Revenue: SNT's revenue is forecast to decline over the next 3 years (-59.4% per year).

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if SNT's Return on Equity is forecast to be high in 3 years time

Discover growth companies

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Syntara Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Price target decreased by 41% to AU$0.20

Forecast to breakeven in 2026

Price target decreased by 32% to AU$0.17

Price target increased to AU$0.58

Analysts lower EPS estimates to -AU$0.014

Price target lowered to AU$0.09

Recent updates

Syntara Limited to Report Q3, 2024 Results on Apr 30, 2024

Syntara Limited's (ASX:SNT) Low P/S No Reason For Excitement

Price target decreased by 41% to AU$0.20

New major risk - Shareholder dilution

Syntara Limited has completed a Follow-on Equity Offering in the amount of AUD 10 million.

Syntara Limited has filed a Follow-on Equity Offering in the amount of AUD 10.0012 million.

New major risk - Financial position

New minor risk - Financial position

Arna Pharma Pty Ltd completed the acquisition of Mannitol respiratory business of Pharmaxis.

Arna Pharma Pty Ltd completed the acquisition of Mannitol respiratory business of Pharmaxis.

New major risk - Revenue and earnings growth

Arna Pharma Pty Ltd entered into definitive agreement to acquire Mannitol respiratory business of Pharmaxis.

Pharmaxis Ltd, Annual General Meeting, Nov 28, 2023

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Forecast to breakeven in 2026

New minor risk - Financial data availability

Price target decreased by 32% to AU$0.17

Second quarter 2023 earnings released: AU$0.008 loss per share (vs AU$0.01 loss in 2Q 2022)

Pharmaxis Ltd Appoints Hashan De Silva to the Board as Nonexecutive Director

Pharmaxis Announces Clinical Trial of Its Topical Anti Scarring Drug PXS6302 Complete Recruitment with the Last of the 42 Patients

Pharmaxis Ltd Announces the Appointment of Simon Green to the Board as an Independent Nonexecutive Director

Pharmaxis Ltd to Report Q3, 2023 Results on Apr 28, 2023

Less than half of directors are independent

First quarter 2023 earnings released

Pharmaxis Ltd, Annual General Meeting, Nov 29, 2022

Pharmaxis Ltd Announces Positive Interim Data from Myelofibrosis Trial

Pharmaxis Ltd Releases Promising Interim Data from Skin Scarring Study

Pharmaxis Ltd Updates on Phase 2 Study of the Pharmaxis Drug Discovery PXS4728

Full year 2022 earnings: Revenues exceed analyst expectations

Pharmaxis Ltd to Report Fiscal Year 2022 Final Results on Aug 23, 2022

Pharmaxis Ltd Announces Resignation of Will Delaat as Non Executive Director

Full year 2022 earnings: Revenues miss analyst expectations

Pharmaxis Limited Announces the Appointment of Dr. Jana Baskar as Chief Medical Officer

Pharmaxis Ltd, Annual General Meeting, Jul 11, 2022

Pharmaxis Ltd to Report Fiscal Year 2022 Results on Aug 11, 2022

Price target increased to AU$0.58

Less than half of directors are independent

We're Hopeful That Pharmaxis (ASX:PXS) Will Use Its Cash Wisely

Second quarter 2022 earnings: Revenues exceed analyst expectations

Pharmaxis Ltd Announces First Patients Dosed in PXS Scar Reduction Trial

Independent Chairman of the Board recently bought AU$113k worth of stock

First quarter 2022 earnings released: AU$0.007 loss per share

Shareholders May Not Be So Generous With Pharmaxis Ltd's (ASX:PXS) CEO Compensation And Here's Why

Pharmaxis Ltd Announces Results of Data Analysis from the Second of Three Stages in Its Phase 1C Clinical Trial (MF-101) Studying Potential New Treatment for the Bone Marrow Cancer Myelofibrosis

Pharmaxis Announces Progression of Clinical Trial in Bone Marrow Cancer

Pharmaxis Ltd announced that it expects to receive AUD 4.366891 million in funding from Karst Peak Capital Limited, BVF Partners, L.P.

Key Things To Understand About Pharmaxis' (ASX:PXS) CEO Pay Cheque

Pharmaxis Announces First Patient Enrolled in Clinical Trial for New Cancer Treatment

Analysts lower EPS estimates to -AU$0.014

Pharmaxis Exports CF Drug to US

Second quarter 2021 earnings released

Revenue and earnings miss expectations

We Think Pharmaxis (ASX:PXS) Can Afford To Drive Business Growth

Pharmaxis Receives USD 7 Million Milestone from Chiesi

Pharmaxis Ltd, Annual General Meeting, Nov 03, 2021

Pharmaxis to Present at Proactive CEO Investor Session

First quarter earnings released

Price target lowered to AU$0.09

Pharmaxis Ltd Auditor Raises 'Going Concern' Doubt

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies